Patents Represented by Attorney James Epperson

Find this attorney in the Justia Lawyer Directory

  • Compounds for the treatment of hepatitis C
    Patent number: 8324212
    Abstract: The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Grant
    Filed: February 22, 2011
    Date of Patent: December 4, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: John F. Kadow, Richard Pracitto
  • CGRP receptor antagonists
    Patent number: 8314117
    Abstract: The disclosure generally relates to the novel compounds of formula I, including pharmaceutically acceptable salts, which are CGRP receptor antagonists. The disclosure also relates to pharmaceutical compositions and methods for using the compounds in the treatment of CGRP related disorders including migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases such as asthma, and chronic obstructive pulmonary disease (COPD).
    Type: Grant
    Filed: October 12, 2010
    Date of Patent: November 20, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Guanglin Luo, Gene M. Dubowchik, John E. Macor
  • Quinuclidine compounds as ?-7 nicotinic acetylcholine receptor ligands
    Patent number: 8309577
    Abstract: The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic ?7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.
    Type: Grant
    Filed: October 28, 2009
    Date of Patent: November 13, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: James H. Cook, II, Ivar M. McDonald, Dalton King, Richard E. Olson, Nenghui Wang, Christiana I. Iwuagwu, F. Christopher Zusi, John E. Macor
  • Compounds for the treatment of hepatitis C
    Patent number: 8309558
    Abstract: The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Grant
    Filed: February 13, 2012
    Date of Patent: November 13, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kap-Sun Yeung, Kyle E. Parcella, John A. Bender, Brett R. Beno, Katharine A. Grant-Young, Ying Han, Piyasena Hewawasam, John F. Kadow, Andrew Nickel
  • Compounds for the treatment of hepatitis C
    Patent number: 8293909
    Abstract: The disclosure provides compounds of formula I, II, III, IV, and V, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Grant
    Filed: March 9, 2010
    Date of Patent: October 23, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Richard Pracitto, John F. Kadow, John A. Bender, Brett R. Beno, Katharine A. Grant-Young, Ying Han, Piyasena Hewawasam, Andrew Nickel, Kyle E. Parcella, Kap-Sun Yeung, Louis S. Chupak
  • Azabicyclo[2.2.1]heptane compounds as alpha-7 nicotinic acetylcholine receptor ligands
    Patent number: 8278320
    Abstract: The disclosure provides compounds of formula I, including Ia, Ib, Ic, or Id, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic ?7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.
    Type: Grant
    Filed: October 19, 2010
    Date of Patent: October 2, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ivar M. McDonald, Robert A. Mate, James H. Cook, II, Dalton King, Richard E. Olson, Nenghui Wang, Christiana I. Iwuagwu, F. Christopher Zusi, Matthew D. Hill, Haiquan Fang, John E. Macor
  • Compounds for the treatment of hepatitis C
    Patent number: 8198449
    Abstract: The disclosure provides compounds of formula I, II, III, IV, and V, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Grant
    Filed: August 28, 2009
    Date of Patent: June 12, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Richard Pracitto, John F. Kadow, John A. Bender, Brett R. Beno, Katharine A. Grant-Young, Ying Han, Piyasena Hewawasam, Andrew Nickel, Kyle E. Parcella, Kap-Sun Yeung, Louis S. Chupak
  • Compounds for the treatment of hepatitis C
    Patent number: 8178523
    Abstract: The disclosure provides compounds of formula (I), including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Grant
    Filed: March 25, 2009
    Date of Patent: May 15, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kap-Sun Yeung, Ying Han, John F. Kadow
  • Compounds for the treatment of hepatitis C
    Patent number: 8148382
    Abstract: The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Grant
    Filed: June 23, 2011
    Date of Patent: April 3, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kap-Sun Yeung, Kyle E. Parcella, John A. Bender, Brett R. Beno, Katharine A. Grant-Young, Ying Han, Piyasena Hewawasam, John F. Kadow, Andrew Nickel
  • Compounds for the treatment of hepatitis C
    Patent number: 8143243
    Abstract: The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.
    Type: Grant
    Filed: February 11, 2009
    Date of Patent: March 27, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Scott W. Martin, Carl P. Bergstrom, Robert G. Gentles, Kap-Sun Yeung
  • Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
    Patent number: 8143244
    Abstract: The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Grant
    Filed: February 23, 2010
    Date of Patent: March 27, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: John A. Bender, Kyle Eastman, John F. Kadow, Zhong Yang
  • CGRP receptor antagonists
    Patent number: 8143403
    Abstract: The disclosure generally relates to the novel compounds of formula I, including their salts, which are CGRP receptor antagonists. The disclosure also relates to pharmaceutical compositions and methods for using the compounds in the treatment of CGRP related disorders including migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases such as asthma, and chronic obstructive pulmonary disease (COPD).
    Type: Grant
    Filed: December 23, 2010
    Date of Patent: March 27, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: David K. Leahy, Yu Fan, Lopa V. Desai, Ronald L. Hanson, Thorsten Rosner, Guanglin Luo
  • Dioxolane and dioxolanone fused indolobenzadiazepine HCV NS5B inhibitors
    Patent number: 8138171
    Abstract: The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV. I.
    Type: Grant
    Filed: March 26, 2009
    Date of Patent: March 20, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: John A. Bender, Zhong Yang, John F. Kadow
  • Compounds for the treatment of hepatitis C
    Patent number: 8133884
    Abstract: The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.
    Type: Grant
    Filed: May 4, 2009
    Date of Patent: March 13, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Scott W. Martin, Carl P. Bergstrom, Min Ding, Xiaofan Zheng, Robert G. Gentles
  • HIV integrase inhibitors
    Patent number: 8129398
    Abstract: The disclosure generally relates to the novel compounds of formula I, including their salts, which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.
    Type: Grant
    Filed: March 18, 2009
    Date of Patent: March 6, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Francis Beaulieu, Carl Ouellet, B. Narasimhulu Naidu, Manoj Patel, Yasutsugu Ueda, Timothy P. Connolly, Jonathan R. Weiss, Michael A. Walker, Nicholas A. Meanwell, Kevin M. Peese, Margaret E. Sorenson, Chen Li
  • Compounds for the treatment of Hepatitis C
    Patent number: 8129367
    Abstract: The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.
    Type: Grant
    Filed: November 18, 2008
    Date of Patent: March 6, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Piyasena Hewawasam, Yong Tu, John A. Bender, Zhong Yang
  • Compounds for the treatment of Hepatitis C
    Patent number: 8124601
    Abstract: The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.
    Type: Grant
    Filed: November 14, 2008
    Date of Patent: February 28, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: John A. Bender, Zhong Yang
  • Pyrrolidine fused indolobenzadiazepine HCV NS5B inhibitors
    Patent number: 8119628
    Abstract: The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.
    Type: Grant
    Filed: March 25, 2009
    Date of Patent: February 21, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Zhong Yang, John A. Bender, John F. Kadow
  • Carboxamide GABA?2 modulators
    Patent number: 8119629
    Abstract: The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating CNS disorders.
    Type: Grant
    Filed: September 29, 2008
    Date of Patent: February 21, 2012
    Assignee: Bristol-Meyers Squibb Company
    Inventor: Ronald J. Mattson
  • Substituted heterocyclic ethers and their use in CNS disorders
    Patent number: 8071778
    Abstract: The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating CNS disorders.
    Type: Grant
    Filed: January 25, 2008
    Date of Patent: December 6, 2011
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael F. Parker, Joanne J. Bronson, Mark V. Silva, Kevin W. Gillman